To find an effective drug for Zika virus, it is important to understand how numerous proteins which are critical for the virus' structure and function interact with their counterparts. One approach to inhibiting the flavivirus is to deter its ability to bind onto glycoproteins; however, the crystal structures of envelope proteins of the ever-evolving viral strains that decipher glycosidic or drug-molecular interactions are not always available. To fill this gap, we are reporting a holistic, simulation-based approach to predict compounds that will inhibit ligand binding onto a structurally unresolved protein, in this case the Zika virus envelope protein (ZVEP), by developing a three-dimensional general structure and analyzing sites at which ligands and small drug-like molecules interact. By examining how glycan molecules and small-molecule probes interact with a freshly resolved ZVEP homology model, we report the susceptibility of ZVEP to inhibition via two small molecules, ZINC33683341 and ZINC49605556-by preferentially binding onto the primary receptor responsible for the virus' virulence. Antiviral activity was confirmed when ZINC33683341 was tested in cell culture. We anticipate the results to be a starting point for drug discovery targeting Zika virus and other emerging pathogens.

Biological Engineering Texas A and M University 303C Scoates Hall 2117 TAMU College Station TX 77843 USA

Department of Virology Veterinary Research Institute Hudcova 70 62100 Brno Czech Republic

Department of Virology Veterinary Research Institute Hudcova 70 62100 Brno Czech Republic Institute of Parasitology Biology Centre of the Czech Academy of Sciences Branisovska 31 37005 Ceske Budejovice Czech Republic

References provided by Crossref.org